• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Presents as Part of the Consumer Analyst Group of New York Conference; Reaffirms 2025 Full-Year Earnings Guidance

    2/19/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email

    Altria Group, Inc. (Altria) (NYSE:MO) is participating in the Consumer Analyst Group of New York Conference in Orlando, Florida today. Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Executive Vice President and Chief Financial Officer, will highlight our exciting progress toward our Vision, discuss how our traditional tobacco businesses continue to support our strategies and provide more detail on our long-term growth aspirations.

    "We believe our actions over time have positioned Altria to win in U.S. nicotine over the long term," said Billy Gifford. "We have a demonstrated commitment to responsibility, an extensive understanding of U.S. nicotine consumers and a compelling portfolio with products in each of today's smoke-free categories. We also have significant cash flows and a flexible balance sheet that support our investments and cash returns to shareholders."

    Remarks and Presentation

    The presentation will be webcast live on www.altria.com in a listen-only mode, beginning at approximately 10:00 a.m. Eastern Time. A copy of the business presentation, prepared remarks and a replay of the webcast will be available at www.altria.com.

    2025 Full-Year Guidance

    We reaffirm our guidance to deliver 2025 full-year adjusted diluted earnings per share (EPS) in a range of $5.22 to $5.37, representing a growth rate of 2% to 5% from a base of $5.12 in 2024. Our guidance includes the impact of one fewer shipping day in 2025, which occurs in the first quarter, assumes limited impact on combustible and e-vapor product volumes from enforcement efforts in the illicit e-vapor market and includes the reinvestment of anticipated cost savings related to our previously announced Optimize & Accelerate initiative (Initiative). The guidance range also includes lower expected net periodic benefit income.

    While our 2025 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. We will continue to monitor conditions related to (i) the economy, including the cumulative impact of inflation, (ii) adult tobacco consumer (ATC) dynamics, including purchasing patterns and adoption of smoke-free products, (iii) illicit product enforcement and (iv) regulatory, litigation and legislative developments.

    Our 2025 full-year adjusted diluted EPS guidance range includes planned investments in support of our Vision, such as (i) marketplace activities in support of our smoke-free products and (ii) continued smoke-free product research, development and regulatory preparation expenses. This guidance range excludes the per share impacts that we expect to record in 2025 related to charges associated with our Initiative.

    Our full-year adjusted diluted EPS guidance range excludes the impact of certain income and expense items that our management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition, disposition and integration-related items, equity investment-related special items, certain income tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the Master Settlement Agreement (NPM Adjustment Items). See Schedule 1 below for the income and expense items for the full-year 2024.

    Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding U.S. generally accepted accounting principles (GAAP) measure for, or reconciliation to, our adjusted diluted EPS guidance.

    Altria's Profile

    We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. Our Vision is to responsibly lead the transition of adult smokers to a smoke-free future (Vision). We are Moving Beyond Smoking™, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.

    Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with a commercialized product portfolio fully covered by marketing granted orders from the U.S. Food and Drug Administration (FDA).

    Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.

    Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world's largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

    The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

    Learn more about Altria at www.altria.com and follow us on X (formerly known as Twitter), Facebook and LinkedIn.

    Forward-Looking and Cautionary Statements

    This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

    Important factors that may cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2023. These factors include the following:

    • our inability to anticipate and respond to changes in ATC preferences and purchase behavior;
    • our inability to compete effectively;
    • the growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume;
    • the risks associated with illicit trade in tobacco products (including counterfeit products, illegally imported products, illicit disposable e-vapor products and oral nicotine pouch products) and the sale of products designed to avoid the regulatory framework for tobacco products, such as products using nicotine analogues, each of which contributes to reductions in the consumption levels and shipment volumes of our businesses' products;
    • our failure to develop and commercialize innovative products, including tobacco products that may reduce health risks relative to other tobacco products and appeal to ATCs;
    • changes, including in macroeconomic and geopolitical conditions (including inflation), that result in shifts in ATC disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;
    • unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans;
    • the risks associated with significant federal, state and local government actions, including FDA regulatory actions and inaction, and various private sector actions;
    • increases in tobacco product-related taxes;
    • our failure to complete or manage successfully strategic transactions, including our acquisition of NJOY and other acquisitions, dispositions, joint ventures and investments in third parties, or realize the anticipated benefits of such transactions;
    • significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions;
    • our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;
    • the risk that we may be required to write down intangible assets, including trademarks and goodwill, due to impairment;
    • the risk that we could decide, or be required, to recall products;
    • the various risks related to health epidemics and pandemics and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;
    • our inability to attract and retain a highly skilled and diverse workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;
    • the risks associated with the various U.S. and foreign laws and regulations to which we are subject due to our international business operations;
    • the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;
    • the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;
    • disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;
    • a downgrade or potential downgrade of our credit ratings;
    • our inability to attract investors due to increasing investor expectations of our performance relating to corporate responsibility factors, including environmental, social and governance matters;
    • the failure of our, or our key service providers' or key suppliers', information systems to function as intended, or cyber-attacks or security breaches affecting us or our key service providers or key suppliers;
    • our failure, or the failure of our key service providers or key suppliers, to comply with laws related to personal data protection, privacy, artificial intelligence and information security;
    • our ability to recognize the expected cost savings in connection with the Initiative or successfully reinvest those savings in our businesses in support of our Vision and 2028 Enterprise Goals, in each case, in the expected manner or timeframe or at all;
    • the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all, including due to macroeconomic and geopolitical conditions; foreign currency exchange rates; ABI's business results; ABI's share price; impairment losses on the value of our investment; our incurrence of additional tax liabilities related to our investment in ABI; and potential reductions in the number of directors that we can have appointed to the ABI board of directors; and
    • the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected manner or timeframe or at all.

    You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

    Schedule 1

    ALTRIA GROUP, INC.

    and Subsidiaries

    Reconciliation of GAAP and non-GAAP Measures

    (dollars in millions, except per share data)

    (Unaudited)

     

     

    Earnings before Income Taxes

    Provision for Income Taxes

    Net Earnings

    Diluted EPS

    2024 Reported

    $

    13,658

     

    $

    2,394

     

    $

    11,264

     

    $

    6.54

     

    NPM Adjustment Items

     

    (27

    )

     

    (7

    )

     

    (20

    )

     

    (0.01

    )

    Acquisition, disposition and integration-related items

     

    (2,527

    )

     

    (665

    )

     

    (1,862

    )

     

    (1.08

    )

    Asset impairment, exit and implementation costs

     

    422

     

     

    107

     

     

    315

     

     

    0.18

     

    Tobacco and health and certain other litigation items

     

    101

     

     

    25

     

     

    76

     

     

    0.04

     

    ABI-related special items

     

    2

     

     

    —

     

     

    2

     

     

    —

     

    Cronos-related special items

     

    18

     

     

    3

     

     

    15

     

     

    0.01

     

    Income tax items

     

    —

     

     

    969

     

     

    (969

    )

     

    (0.56

    )

    2024 Adjusted for Special Items

    $

    11,647

     

    $

    2,826

     

    $

    8,821

     

     

    5.12

     

    While we report our financial results in accordance with GAAP, our management reviews certain financial results, including diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under "2025 Full-Year Guidance" in the release. Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating capital and other resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with GAAP, and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250218457455/en/

    Altria Client Services

    Investor Relations

    804-484-8222

    Altria Client Services

    Media Relations

    804-484-8897

    www.altria.com/contact-us/media

    Get the next $MO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    11/10/2022$38.00Neutral → Sell
    UBS
    6/29/2022$53.00 → $36.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altria to Host Webcast of 2025 Annual Meeting of Shareholders

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2025 Annual Meeting of Shareholders ("2025 Annual Meeting" or "meeting") on Thursday, May 15, 2025 at 9:00 a.m. Eastern Time. The 2025 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2025 Annual Meeting record date (March 25, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2025 Proxy Statement. If you are not a shareholder

      5/1/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria to Host Webcast of 2025 First-Quarter Results

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Tuesday, April 29, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 first-quarter business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 first-quarter business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is necessary; directions are posted at www.

      4/15/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Altria downgraded by Deutsche Bank

      Deutsche Bank downgraded Altria from Buy to Hold

      4/1/25 3:04:54 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Altria with a new price target

      Morgan Stanley initiated coverage of Altria with a rating of Equal-Weight and set a new price target of $54.00

      1/16/25 7:47:52 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria upgraded by BofA Securities with a new price target

      BofA Securities upgraded Altria from Neutral to Buy and set a new price target of $65.00 from $55.00 previously

      12/6/24 7:56:47 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Altria Group Inc.

      10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/29/25 7:26:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/29/25 7:03:23 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Altria Group Inc.

      DEFA14A - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/3/25 9:03:17 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:08:44 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:03:21 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Financials

    Live finance-specific insights

    See more
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on April 30, 2025 to shareholders of record as of March 25, 2025. The ex-dividend date is March 25, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250227441410/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

      2/27/25 3:00:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2024 Fourth-Quarter and Full-Year Results; Provides 2025 Full-Year Earnings Guidance; Announces New $1 Billion Share Repurchase Program

      Altria Group, Inc. (NYSE:MO) today reports our 2024 fourth-quarter and full-year business results and provides our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "2024 was another pivotal year for Altria, headlined by meaningful progress toward our Vision, strong financial results and significant cash returns to shareholders," said Billy Gifford, Altria's Chief Executive Officer. "Our companies' leading brands and talented teams enabled our core tobacco businesses to deliver solid income growth and margin expansion, while we strategically invested in our future." "We expect to deliver 2025 full-year adjusted diluted EPS in a range of $5.22 to $5.37. This range re

      1/30/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/24 4:58:48 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/23 2:49:28 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/9/23 10:54:46 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gifford William F. Jr. was granted 31,037 shares and covered exercise/tax liability with 37,243 shares, decreasing direct ownership by 0.89% to 689,127 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      4/18/25 2:45:32 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Gifford William F. Jr. was granted 48,911 shares and covered exercise/tax liability with 55,488 shares, decreasing direct ownership by 0.94% to 695,333 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      3/3/25 3:08:57 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SVP, Chief HR Off. & CCO Whitaker Charles N. was granted 8,568 shares and covered exercise/tax liability with 7,511 shares, increasing direct ownership by 0.57% to 187,627 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      3/3/25 3:08:49 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    See more
    • Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

      Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

      2/26/24 4:30:00 PM ET
      $ARIS
      $MO
      $PXD
      Oilfield Services/Equipment
      Energy
      Medicinal Chemicals and Botanical Products
      Health Care
    • Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

      -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

      1/23/24 9:00:00 AM ET
      $ARIS
      $LBC
      $MO
      Oilfield Services/Equipment
      Energy
      Major Banks
      Finance
    • Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

      Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

      10/25/23 4:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care